XOSPATA (gilteritinib) tablets is used to treat acute myeloid leukemia (AML). XOSPATA (gilteritinib) tablets, for oral use can be imported for personal use under "patient name basis" treatment in India. Brand gilteritinib Can be imported and made available on "Patient Name basis" treatment in India. For this applicant is required to make an request application with required document. IPN, New Delhi will do the necessary process to obtain permission from Drugs Controller General (India) to import.
Therapeutic indications and Usage
XOSPATA is a kinase inhibitor indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.
If you have any questions about your illness, talk to your doctor
Active ingredient: gilteritinib Inactive ingredients: mannitol, hydroxypropyl cellulose, low-substituted hydroxypropyl cellulose, magnesium stearate, hypromellose, talc, polyethylene glycol, titanium dioxide and ferric oxide.
MANUFACTURER: Astellas Pharma Inc.
DOSAGE FORMS AND STRENGTHS: 40 mg tablet: light yellow, round-shaped film-coated tablet debossed with the Astellas logo and ‘235’ on the same side.
MEDICINE APPROVED BY: European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada, Therapeutic Goods Administration (TGA Source Details: Patient Information
Patient Name Basis Treatment IPN, New Delhi can facilitate patient to import of "XOSPATA (gilteritinib) tablets" in small quantities for personal use. For this applicant is required to make an application in Form 12A, along with the prescription of the Registered Medical Practitioner (RMP).
Healthcare Professional In India
If you have any question, please email IPN Support Team or Call Indian Pharma Network for XOSPATA (gilteritinib) tablets price list or cost in India. on
Mr. Tarun:- +91 9891 296 838
Mr. Neeraj:- +91 9811 747 774
We are the facilitator, group of highly qualified healthcare professionals, provide solutions on how to get access of anti cancer medicines not available in India. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India, IPN, New Delhi procure drugs on behalf of patient.
XOSPATA is a kinase inhibitor indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF).
Source content : www.accessdata.fda.gov
IPN, New Delhi can facilitate patient to import of "XOSPATA (gilteritinib) tablets" in small quantities for personal use. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.
For procurement cost of XOSPATA (gilteritinib) tablets in India, Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the XOSPATA (gilteritinib) tablets medicine cost price in India.
The order for XOSPATA (gilteritinib) tablets will be confirmed only after
1. submitting Form 12A, along with the prescription of the Registered Medical Practitioner (RMP).
2. Permission from obtained from the office of the Drugs Controller General (India).
3. Availability of XOSPATA (gilteritinib) tablets from authorised distributor.
Gilteritinib, sold under the brand name Xospata, is an anti-cancer drug. It acts as an inhibitor of FLT3, hence it is a tyrosine kinase inhibitor. It was developed by Astellas Pharma. In April 2018, Astellas filed a new drug application with the Food and Drug Administration for gilteritinib for the treatment of adult patients with FLT3 mutation–positive relapsed or refractory acute myeloid leukemia (AML).
In November 2018, the FDA approved gilteritinib for treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test. Gilteritinib was granted orphan drug status by the U.S. FDA, the European Commission (EC) and the Japan Ministry of Health, Labor and Welfare, for some AML patients. Gilteritinib was approved for medical use in Australia in March 2020.
XOSPATA (gilteritinib) tablets , for oral use. Initial U.S. Approval: 2019
Capsules: 100 mg.
For XOSPATA (gilteritinib)Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details
FDA approves treatment for adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a certain genetic mutation For More Details
FDA Approves Update to Gilteritinib AML Label to Include OS Data For More Details
Step 1. Send a request for your medicine online:-Applicant is required to make an application in Form 12A, along with the prescription of the Registered Medical Practitioner (RMP).
Step 2. Verification of documents:-We verify your a prescription and necessary documents to import drugs in small quantities for personal use.
Step 3. Permission to Import:-After getting approval of Drugs Controller General (India), we start the process to import of drugs as mentioned in prescription for personal use.
Step 4. We source your medicine:-Our expert sourcing team work with our global network of suppliers to find you the best price. Once we have found you the lowest possible cost for your medicine, we will present you with a final offer for your approval.
Step 5. Delivery of medicine:-After you have accepted our offer, our experienced logistics team will arrange all the shipping and transportation of your medicine.
Doctor’s Prescription –
We would require prescription from Registered Medical Practitioner (RMP) stating product name, dosage, duration of treatment and diagnosis.
Patient’s Medical history –
We would require all test reports and medical reports of the patient for last 3 months.
Patient’s Identity card –
We will require scan copy of patient’s identity card and proof of residence to initiate documentation process.
Almost all countries across the world have provisions for granting access to drugs prior to marketing approval for personal use for patients who have exhausted all other treatment options available in their country. Indian Pharma Network, New Delhi can help patients in accessing/importing Ant-cancer medicines, unapproved in their home country against a legitimate prescription and in conformity with all local laws and regulations of their home country.
Send your query to find out -
XOSPATA (gilteritinib) price in South East Asia – China (Beijing, Chongqing, Shanghai, Tianjin and Shenzhen), Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong.
XOSPATA (gilteritinib) price in United Arab Emirates – Iraq, Iran, Saudi Arabia, Jordan.
XOSPATA (gilteritinib) price in North America – Mexico.
XOSPATA (gilteritinib) price in South America – Argentina, Brazil, Chile, Colombia, Peru, Venezuela.
XOSPATA (gilteritinib) price in Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia.
XOSPATA (gilteritinib) price in Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia.
XOSPATA (gilteritinib) price in African Countries – Algeria, Mauritius, Uganda, Zimbabwe.
XOSPATA (gilteritinib) price in Australia and New Zealand.
Your order will be shipped to you by our partner couriers, such as DHL, UPS and specialised cold chain couriers. If you would like your order to be shipped by a specific courier, please inform us when you place the order. Our standard delivery time varies from 5 to 10 working days. The shipping cost depends on the medicine and the destination country. After making an enquiry, you will receive a detailed quote that includes the shipping costs.